Nasdaq

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative ...

Previous Phase 1b clinical data suggest niclosamide delivers favorable efficacy compared to topical corticosteroid in the treatment of ulcerative proctitis and ulcerative proctosigmoiditis BOCA RATON, ...
Business Insider

Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel DiseaseStudy to help guide Cellceutix in ...

BEVERLY, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, ...
Healio

Case 1: Results/Discussion

Eugenia Uche-Anya, MD, MPH, gastroenterology fellow at Massachusetts General Hospital, discusses the results of the case and important points to keep in mind when treating patients with mild UC: ...
Business Insider

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Indices Commodities Currencies Stocks ...